Themis Medicare has informed that as per the Company's minimum Standards Code of Conduct to regulate, monitor and report trading by its Employees and other Connected Persons under SEBI (Prohibition of Insider Trading) Regulations, 2015 (as amended) (PIT Regulations) and pursuant to BSE Circular Ref No: LIST/COMP /01/2019-20 dated 2nd April, 2019 and NSE Circular Ref No. NSE/CML/2019/11 on the provisions of Clause 4 of the Schedule B of the PIT regulations, the Trading Window for dealing in the Securities of the Company shall remain closed on and from Sunday, 1st October, 2023 and will re-open after completion of 48 hours from the declaration of financial results for the quarter and half year ended 30th September, 2023 by the Board of Directors of the Company. The same has been intimated to all the directors, officers and designated employees of the Company. Further the date of Board Meeting for considering the said financial results for the quarter and half year ended 30th September, 2023 shall be intimated in due course.
The above information is a part of company’s filings submitted to BSE.
Company Name | CMP |
---|---|
Sun Pharma Inds. | 1532.85 |
Dr. Reddys Lab | 5812.50 |
Cipla | 1403.90 |
Zydus Lifesciences | 1104.45 |
Lupin | 1661.90 |
View more.. |